|Awarded On||February 15, 2023|
|Title||A novel combination therapeutic approach to revitalizing immunotherapy for bone metastatic prostate cancer|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Sue-Hwa Lin|
|Cancer Sites||Bone, Prostate|
*Pending contract negotiation
Prostate cancer (PCa) is dominated by complications arising from bone metastasis, which often has a lethal outcome. Currently, immunotherapeutic approach for prostate cancer is limited because PCa bone metastasis is resistant to immune checkpoint therapy. This study aims to develop a novel combination therapeutic approach to revitalize immunotherapy in bone metastatic prostate cancer. PCa bone metastasis is unique in that the bone lesions tend to be bone forming rather than bone lysing, which occurs in other cancers. Our studies established that PCa-induced aberrant bone formation recruits immunosuppressive myeloid cells that leads to resistance to immune checkpoint therapy. Our propos...